Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | ACACA | Q13085 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | AOC2 | O75106 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25912482 | 0.93 | ALDH1A1 (0.41) | OPRM1ALDH1A1LMNACRBNACACB | |
| SCHEMBL25912761 | 0.84 | ALDH1A1 (0.39) | OPRM1ALDH1A1LMNAACACBACACA | |
| SCHEMBL23342178 | 0.82 | CRBN (0.36) | CRBNACACBACACARIPK1AOC2 | |
| SCHEMBL23338590 | 0.77 | ACACB (0.33) | CRBNACACBACACARIPK1AOC2 | |
| SCHEMBL23342004 | 0.75 | ACACB (0.38) | CRBNACACBACACARIPK1AOC2 | |
| SCHEMBL23342007 | 0.75 | AOC2 (0.34) | ALDH1A1ACACBACACARIPK1AOC2 | |
| SCHEMBL23342183 | 0.75 | OPRM1 (0.40) | OPRM1ALDH1A1LMNA | |
| SCHEMBL17118711 | 0.74 | CYP3A4 (0.38) | OPRM1ALDH1A1CRBNOPRL1 | |
| SCHEMBL22156260 | 0.73 | CHRM2 (0.38) | OPRM1ACACBACACAAOC2PRMT1 | |
| SCHEMBL12758823 | 0.73 | OPRM1 (0.34) | OPRM1ACACBACACAAOC2OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | OPRM1 4485/4885ALDH1A1 4528/4885LMNA 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.